首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >Differences in the Basic Pharmacology of Beta-Blocking Agents
【24h】

Differences in the Basic Pharmacology of Beta-Blocking Agents

机译:β受体阻滞剂基本药理学的差异

获取原文
获取原文并翻译 | 示例
           

摘要

beta-Blockers are important in the treatment of arterial hy-pertension, coronary heart disease, cardiac arrhythmias and heart failure. Their effects are mediated by the block-ade of various types of (3- and alpha-receptors, and compounds have been developed to specifically inhibitthem.Nonselective beta-blockers (e.g. propranolol, nadolol, pen-butolol and carvedilol) differ from beta-selective blockers (e.g.metoprolol, atenolol, bisoprolol and nebivolol). Selectivity is never absolute and all beta-blockers can causeproblems in allergic asthma including serious side effects and death. The clinical advantage of selectivity appears to be meager, as only few patients with chronic obstructive pulmonary disease seem to benefit from increased tolerability.
机译:β受体阻滞剂在治疗动脉炎,冠心病,心律不齐和心力衰竭的治疗方面很重要。 它们的作用是由各种类型的(3-和α受体的块)介导的,并且已经开发出化合物特异性抑制剂。非稳态β受体阻滞剂(例如普萘洛尔,Nadolol,pen-butolol和Carvedilol) 选择性阻滞剂(例如甲莫洛洛尔,阿替洛尔,双丙洛洛尔和奈比洛尔)。选择性绝不是绝对的,所有β受体阻滞剂都可以在过敏性哮喘中疾病性疾病,包括严重的副作用和死亡。选择性的临床优势似乎是MEAGER的,因为只有少数具有慢性患者 阻塞性肺部疾病似乎受益于增加的耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号